The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shilov Y.E.

Mental Health Research Center

Baimeeva N.V.

Clinical diagnostic laboratory of EuroTest LLC

Brusov O.S.

Mental Health Research Center

Oleichik I.V.

Mental Health Research Centre

Sizov S.V.

Mental Health Research Center

Tyurin I.A.

N.V. Sklifosovsky Research Institute of Emergency Medicine of Department of Health of Moscow

Cinnabarinic acid as a potential prognostic marker of schizophrenia

Authors:

Shilov Y.E., Baimeeva N.V., Brusov O.S., Oleichik I.V., Sizov S.V., Tyurin I.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12): 138‑142

DOI: 10.17116/jnevro2022122121138

Read: 1640 times

Contact the author
Table of contents

CINNABARINIC ACID AS A POTENTIAL PROGNOSTIC MARKER OF SCHIZOPHRENIA
CINNABARINIC ACID AS A POTENTIAL PROGNOSTIC MARKER OF SCHIZOPHRENIA

To cite this article:

Shilov YE, Baimeeva NV, Brusov OS, Oleichik IV, Sizov SV, Tyurin IA. Cinnabarinic acid as a potential prognostic marker of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12):138‑142. (In Russ.)
https://doi.org/10.17116/jnevro2022122121138

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Age transformation of leading clinical diagnoses in adolescents and young people with non-suicidal self-harm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):48-56
Constitutional and morphological bases of suicidal beha­vior in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):52-56
Search for risk factors for slowed intra-atrial conduction in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):111-116
Search for neurophysiological markers of schi­zophrenia spectrum diso­rders: ocular microtremor and contrast sensitivity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):228-236
Transcranial electrostimulation as part of combination therapy for mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):37-44
Prognostic value of athe­rogenicity indi­ces in schi­zophrenia patients with meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(3):155-160
Serum NOS1AP concentration: asso­ciation with clinical schi­zophrenia poly­morphism and meta­bolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(3):167-173
Prospects for retroelement-targeted therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4):22-27
Effect of aripiprazole on cyto­kine production by T cells in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4):89-95
Abstract:

OBJECTIVE

To develop a method for determining cinnabarinic acid (CA) and its immediate precursor 3-hydroxyanthranylic acid (3HAA) in blood plasma and to study their concentrations in patients with schizophrenia before and after treatment.

MATERIAL AND METHODS

The study was carried out on a sample of 23 female patients with an attack-like progredient schizophrenia (F20.01). The levels of CA and 3HAA in blood plasma were measured using liquid chromatography with tandem mass spectrometry.

RESULTS

We found an inverse statistically significant correlation of the sum of CA and 3HAA concentrations before treatment with the total PANSS score after treatment (R=–0.50; p<0.05). There was also an inverse correlation of the CA concentration of before treatment with the total PANSS score after treatment (R=–0.41, p=0.052), statistically significant at the trend level (0.05<p<0.1).

CONCLUSION

CA concentrations in human blood were determined for the first time. The obtained correlations with clinical data show the potential prognostic significance of determining the levels of CA and 3HAA in blood plasma and increase the relevance of further studies.

Keywords:

cinnabarinic acid
3-hydroxyanthranilic acid
kynurenine pathway
schizophrenia

Authors:

Shilov Y.E.

Mental Health Research Center

Baimeeva N.V.

Clinical diagnostic laboratory of EuroTest LLC

Brusov O.S.

Mental Health Research Center

Oleichik I.V.

Mental Health Research Centre

Sizov S.V.

Mental Health Research Center

Tyurin I.A.

N.V. Sklifosovsky Research Institute of Emergency Medicine of Department of Health of Moscow

Received:

21.04.2022

Accepted:

18.07.2022

Close metadata

References:

  1. Muneer A. Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations. Clin Psychopharmacol Neurosci. 2020;18(4):507-526.  https://doi.org/10.9758/cpn.2020.18.4.507
  2. de Carvalho LP, Bochet P, Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochemistry Int. 1996;28(4):445-452.  https://doi.org/10.1016/0197-0186(95)00091-7
  3. Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2017;112(Pt B):297-306.  https://doi.org/10.1016/j.neuropharm.2016.05.020
  4. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-477.  https://doi.org/10.1038/nrn3257
  5. Wonodi I, Stine OC, Sathyasaikumar KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011;68(7):665-674.  https://doi.org/10.1001/archgenpsychiatry.2011.71
  6. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4-15.  https://doi.org/10.1038/npp.2011.181
  7. Plitman E, Iwata Y, Caravaggio F, et al. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2017;43(4):764-777.  https://doi.org/10.1093/schbul/sbw221
  8. Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75-83.  https://doi.org/10.1093/schbul/sbx035
  9. Lowe MM, Mold JE, Kanwar B, et al. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One. 2014;9(2):e87877. Published 2014 Feb 3.  https://doi.org/10.1371/journal.pone.0087877
  10. Pasceri R, Siegel D, Ross D, Moody CJ. Aminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin A. J Med Chem. 2013;56(8):3310-3317. https://doi.org/10.1021/jm400049z
  11. Fazio F, Lionetto L, Molinaro G, et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol. 2012;81(5):643-656.  https://doi.org/10.1124/mol.111.074765
  12. Nicoletti F, Orlando R, Di Menna L, et al. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Front Psychiatry. 2019;10:49. Published 2019 Feb 14.  https://doi.org/10.3389/fpsyt.2019.00049
  13. Maksymetz J, Moran SP, Conn PJ. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain. 2017;10(1):15. Published 2017 Apr 26.  https://doi.org/10.1186/s13041-017-0293-z
  14. Fazio F, Zappulla C, Notartomaso S, et al. Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology. 2014;81:237-243.  https://doi.org/10.1016/j.neuropharm.2014.02.011
  15. Fraguas D, Díaz-Caneja CM, Ayora M, et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophr Bull. 2019;45(4):742-751.  https://doi.org/10.1093/schbul/sby125
  16. Orlovska-Waast S, Köhler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis [published correction appears in Mol Psychiatry. 2019 Mar 12]. Mol Psychiatry. 2019;24(6):869-887.  https://doi.org/10.1038/s41380-018-0220-4
  17. Ulivieri M, Wierońska JM, Lionetto L, et al. The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. Schizophr Bull. 2020;46(6):1471-1481. https://doi.org/10.1093/schbul/sbaa074
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.